MX9302279A - Metodo para la produccion del factor viii presenteen el plasma, altamente purificado. - Google Patents

Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.

Info

Publication number
MX9302279A
MX9302279A MX9302279A MX9302279A MX9302279A MX 9302279 A MX9302279 A MX 9302279A MX 9302279 A MX9302279 A MX 9302279A MX 9302279 A MX9302279 A MX 9302279A MX 9302279 A MX9302279 A MX 9302279A
Authority
MX
Mexico
Prior art keywords
factor viii
production
highly purified
plasma
viii present
Prior art date
Application number
MX9302279A
Other languages
English (en)
Inventor
Yendra Linnau
Otto Schwarz
Peter Turecek
Gunther Wober
Johann Eibl
Friedrich Elsinger
Herbert Gritsch
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3501200&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9302279(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of MX9302279A publication Critical patent/MX9302279A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona con un método para la producción del factor VII altamente purificado de virus. El método incluye una combinación de las siguientes mediciones: a) purificación cromatográfica de una fracción que contiene el factor VIII; b) tratamiento con tensida del factor VIII en solución acuosa en una relación tensida/proteína de 1:1 a 1000:1, y c) tratamiento térmico de la preparación de factor VIII en el estado sólido.
MX9302279A 1992-04-24 1993-04-20 Metodo para la produccion del factor viii presenteen el plasma, altamente purificado. MX9302279A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0084992A AT399818B (de) 1992-04-24 1992-04-24 Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation

Publications (1)

Publication Number Publication Date
MX9302279A true MX9302279A (es) 1994-08-31

Family

ID=3501200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302279A MX9302279A (es) 1992-04-24 1993-04-20 Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.

Country Status (18)

Country Link
US (1) US5410022A (es)
EP (1) EP0567448B2 (es)
JP (1) JP2511631B2 (es)
AT (2) AT399818B (es)
AU (1) AU659301B2 (es)
BR (1) BR9301641A (es)
CA (1) CA2094347C (es)
CZ (1) CZ279979B6 (es)
DE (1) DE59308628D1 (es)
DK (1) DK0567448T4 (es)
ES (1) ES2117703T5 (es)
FI (1) FI106468B (es)
HU (1) HU210632B (es)
MX (1) MX9302279A (es)
NO (1) NO307465B1 (es)
PL (1) PL172462B1 (es)
SK (1) SK279750B6 (es)
ZA (1) ZA932843B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
AT402788B (de) * 1993-08-03 1997-08-25 Immuno Ag Virussichere blutgerinnungsfaktor xiii-präparation
DE4337573C1 (de) * 1993-11-04 1995-05-18 Octapharma Ag Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
DE4407837C1 (de) * 1994-03-09 1995-08-17 Octapharma Ag Verfahren zur Gewinnung von hochreinem, virusinaktiviertem alpha¶1¶-Antitrypsin mittels Anionenaustauscher-Chromatographie
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
PT2193809E (pt) 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
US20040117862A1 (en) * 2002-03-11 2004-06-17 Cooper Julian D. Production of high levels of transgenic factor VII with engineered stability and its therapeutic uses
EP1848812A4 (en) * 2004-10-01 2011-11-09 Life Technologies Corp SUPPLY BUFFERS, SYSTEMS AND METHODS FOR THE IN VITRO SYNTHESIS OF BIOMOLECULES
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
CN101967188B (zh) * 2010-11-08 2012-11-28 江西博雅生物制药股份有限公司 一种人凝血因子ⅷ的制备工艺
MX391630B (es) * 2014-11-05 2025-03-19 Abbott Laboratories Gmbh Procesos para la producción de composiciones con perfil de seguridad mejorado teniendo actividad lipasa y composiciones adecuadas para medicamentos

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT218391B (de) 1959-01-26 1961-11-27 Anton Daxboeck Vorrichtung zur Sicherung einer Türschloßfalle, insbesondere für Kraftfahrzeuge
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
FR2435832A1 (fr) * 1978-07-21 1980-04-04 Alsthom Cgee Dispositif de connexion electrique
US4250139A (en) * 1979-02-01 1981-02-10 Collagen Corporation Microwave sterilization of dry protein
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE3176491D1 (en) * 1980-03-05 1987-11-26 Miles Lab Pasteurized therapeutically active protein compositions
US4314997A (en) * 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
DE3043857A1 (de) * 1980-11-21 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ii und vii
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) * 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4379085A (en) * 1982-05-14 1983-04-05 American National Red Cross Heat stabilization of plasma proteins
US4511556A (en) * 1982-06-10 1985-04-16 The United States Of America As Represented By The Department Of Health And Human Services Inactivation of a lipid virus
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6054287B2 (ja) * 1983-10-19 1985-11-29 株式会社ミドリ十字 血漿蛋白の加熱処理方法
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
DE3432083A1 (de) * 1984-08-31 1986-03-06 Behringwerke Ag, 3550 Marburg Pasteurisierte, isoagglutininfreie faktor viii-praeparation und verfahren zu ihrer herstellung
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT391808B (de) * 1986-11-03 1990-12-10 Immuno Ag Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion
AT388501B (de) * 1987-02-12 1989-07-25 Immuno Ag Verfahren zur herstellung von parenteral verabreichbaren blutprodukten
WO1988008710A1 (en) * 1987-05-15 1988-11-17 Rubinstein Alan I Sequential improved method for treatment of human blood-clotting factor products
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
AT391809B (de) * 1988-01-12 1990-12-10 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutplasmaprodukten
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
EP0343275B1 (de) * 1988-05-27 1993-02-03 Centre Regional De Transfusion Sanguine De Lille Verfahren zur Herstellung eines hochreinen, virusfreien Antihämophiliefaktors mittels Chromatographie
AT397203B (de) * 1988-05-31 1994-02-25 Immuno Ag Gewebeklebstoff
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
EP0367840B1 (de) * 1988-11-05 1993-02-03 Octapharma AG Verfahren zur Herstellung eines hochreinen, nicht infektiösen Antihämophiliefaktors mittels Chromatographie
US5156973A (en) * 1988-11-23 1992-10-20 Edward Shanbrom Antiviral blood sampling process and apparatus
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
CA2007545A1 (en) * 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
JP3297433B2 (ja) * 1989-06-15 2002-07-02 ローヌ−プーラン ローラー インターナショナル （ホウルディングス） インコーポレイテッド ウイルスで汚染された薬理組成物中のウイルスの不活性化方法
IE73210B1 (en) * 1990-01-24 1997-05-07 Warner Lambert Co Process for the production of thrombin and high purity thrombin preparation thereby obtained
US5217737A (en) * 1991-05-20 1993-06-08 Abbott Laboratories Plastic containers capable of surviving sterilization
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
FR2681867B1 (fr) * 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins Procede de purification du facteur viii et preparations obtenues.
AT398079B (de) * 1991-11-04 1994-09-26 Immuno Ag Präparation mit thrombinaktivität sowie verfahren zu ihrer herstellung
FR2841484B1 (fr) * 2002-06-26 2004-09-10 Boucq De Beaudignies Ghisla Le Dispositif et procede de filtration de l'air et des gaz avec regeneration des particules captees

Also Published As

Publication number Publication date
FI106468B (fi) 2001-02-15
US5410022A (en) 1995-04-25
EP0567448B1 (de) 1998-06-03
SK279750B6 (sk) 1999-03-12
JP2511631B2 (ja) 1996-07-03
PL298670A1 (en) 1994-04-05
DK0567448T4 (da) 2005-05-02
AU3687593A (en) 1993-10-28
BR9301641A (pt) 1993-10-26
HU210632B (en) 1995-06-28
CZ69293A3 (en) 1993-12-15
AU659301B2 (en) 1995-05-11
FI931826A0 (fi) 1993-04-22
CZ279979B6 (cs) 1995-09-13
JPH069694A (ja) 1994-01-18
DK0567448T3 (da) 1999-03-22
NO931476L (no) 1993-10-25
NO931476D0 (no) 1993-04-22
HUT64777A (en) 1994-02-28
CA2094347C (en) 2002-06-25
AT399818B (de) 1995-07-25
ES2117703T5 (es) 2005-07-16
CA2094347A1 (en) 1993-10-25
ATA84992A (de) 1994-12-15
EP0567448B2 (de) 2005-01-05
DE59308628D1 (de) 1998-07-09
NO307465B1 (no) 2000-04-10
FI931826L (fi) 1993-10-25
ZA932843B (en) 1993-11-23
SK39193A3 (en) 1993-11-10
ATE166881T1 (de) 1998-06-15
ES2117703T3 (es) 1998-08-16
HU9301038D0 (en) 1993-06-28
EP0567448A1 (de) 1993-10-27
PL172462B1 (pl) 1997-09-30

Similar Documents

Publication Publication Date Title
MX9302279A (es) Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.
NO302366B1 (no) 4-merkaptoacetylamino-£2|benzazepinon(3)-derivater, og farmasöytisk preparat
ES2071706T3 (es) Metodo para fraccionar proteinas plasmaticas.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
EA199901031A1 (ru) Производные бензимидазола
EP0564739A3 (es)
ES2126122T3 (es) Nitrato-aminoacido-disulfuros para la terapia de enfermedades del sistema cardio-circulatorio.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2057191T5 (es) Metodo de produccion para una composicion que contiene proteinas.
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2138603T3 (es) Procedimiento para el aislamiento de los factores ix, x y ii altamente purificados a partir del complejo protrombinico o del plasma humano.
IT1264545B1 (it) Procedimento per la preparazione della diacereina
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
NO902499L (no) Fremgangsmaate for fremstilling av rensede albuminopploesninger.
MX9203011A (es) Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
ATE27157T1 (de) Cycloalkylderivate von benzisoselenazolonen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
NO960927D0 (no) Fremgangsmåte ved fremstilling av 9-(2-hydroksy)-etoksymetylguanin
ES2135023T3 (es) Utilizacion de un decapeptido con actividad de tipo benzodiazepina para la preparacion de medicamentos y complementos alimentarios.
DK0538690T3 (da) Arylquinolyl-substituerede 1,4-dihydropyridin-dicarboxylsyrederivater, fremgangsmåde til deres fremstilling af deres anvendelse i lægemidler
ES2117197T3 (es) Procedimiento para la extraccion y purificacion de alfa1-antitripsina (alfa1-pi) a partir de la fraccion de cohn iv-1.
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
MX9303985A (es) Nucleosidos terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees